Pfizer

A new study suggests vaccinating pregnant women protects their newborns from the common but scary respiratory virus called RSV.

Pfizer is asking the Food and Drug Administration to expand use of its updated COVID-19 booster shot to children ages 5 to 11.

The Centers for Disease Control and Prevention is now recommending omicron-specific COVID-19 booster shots for people 12 and older. Here’s how to get yours in all the New England states. The new booster from Pfizer-BioNtech and Moderna are bivalent vaccines, which means they target two strains — in this case the original SARS-CoV-2 and the omicron BA.5 subvariant, which is…

The patent infringement lawsuits were filed in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany, according to a news release.

Moderna sued Pfizer and its German partner BioNTech on Friday, alleging that the two companies copied Moderna’s technology in developing their COVID-19 vaccine Comirnaty. Moderna said in a news release that Pfizer and BioNTech infringed on patents filed between 2010 and 2016 covering its mRNA technology, which Moderna used to develop its own COVID-19 vaccine, Spikevax.

The findings reflect the changing nature of the pandemic, in which the vast majority of people already have some protection against the virus due to vaccination or prior infection.

Pfizer has asked U.S. regulators to authorize its combination COVID-19 vaccine that adds protection against the newest omicron strains: the BA.4 and BA.5 variants.

Now entering late-stage clinical trials, the vaccine could be approved as soon as 2025.

There are currently no approved vaccines for Lyme Disease, but that could soon change.

The Pfizer pill, Paxlovid, is intended for people with COVID-19 who are more likely to become seriously ill. Previously only doctors could prescribe the drug

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection.

Parents of children under 5 are weighing their options now that the COVID vaccines from Pfizer and Moderna have been approved for them.

This weekend, the CDC approved the use of the vaccines for kids between the ages of six months and four years, a year and a half after adults received their first jab. But there seems to be some division among parents. A national survey last month found 18% of parents with kids under five would get them vaccinated as...

The FDA must still decide whether to take the recommendations and approve the COVID-19 vaccine for kids between six months and 5 years old.

Some people who take Paxlovid, an antiviral for COVID-19, see their symptoms rebound after briefly recovering, prompting concerns about taking the drug at all. The Centers for Disease Control and Prevention issued in an advisory about the phenomenon last month. Since then, doctors and infectious disease experts in Boston have been flooded with questions from their patients about the drug,...

COVID-19 shots for U.S. infants, toddlers and preschoolers moved a step closer Wednesday.

Top Boston doctors explain talk about increasing cases in the U.K., the BA.4, BA.5 subvariants rising in New England and a study with new insight on why some people experience long COVID during NBC10 Boston’s weekly series, “COVID Q&A.”

The White House has announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S. as it projects COVID-19 infections will continue to spread over the summer travel season. The nation’s first federally backed test-to-treat site is opening Thursday in Rhode Island. The site will provide patients with immediate access to the drug once they test positive....

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries. That includes its top-selling COVID-19 vaccine and treatment. The pharmaceutical giant said early Wednesday that it is launching a program aimed at improving health equity in 45 lower-income countries. Most of those nations are in Africa. The drugmaker aims to provide...

Pfizer says it will seek emergency use authorization for a three-dose course of its COVID-19 vaccine in pediatric patients ages 6 months to 5 years old after publishing data from it’s latest study.